GTB-3550 TriKE which is a primal construct with CD16 scFv and targets on CD33+ AML and myelodysplastic syndromes (MDS) is the first TriKE in phase I clinical trials (NCT03214666) [7, 12]. Here, CD33 is linked to acute myeloid leukemia.